# GH55 for Advanced Cancers With MAPK Mutations: A Study on Safety and Early Results

> **NCT06310382** · PHASE1,PHASE2 · RECRUITING · sponsor: **Suzhou Genhouse Bio Co., Ltd.** · enrollment: 110 (estimated)

## Conditions studied

- Advanced Solid Tumors With MAPK Signal Pathway Mutations

## Interventions

- **DRUG:** GH55

## Key facts

- **NCT ID:** NCT06310382
- **Lead sponsor:** Suzhou Genhouse Bio Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-12-07
- **Primary completion:** 2025-05-26
- **Final completion:** 2025-08-04
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2024-07-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06310382

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06310382, "GH55 for Advanced Cancers With MAPK Mutations: A Study on Safety and Early Results". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06310382. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*